ポリゲニックリスクスコアガイドによる個別化骨粗鬆症スクリーニング:集団ベースの研究
Dongxue Wang1, Wen Sun1, Di Liu1
1Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
BMC medicine
|January 14, 2026
まとめ
PRSによる個別化骨粗鬆症スクリーニングは、現在のガイドラインよりも数年早くリスクの高い女性を特定できます。この精密アプローチは、骨粗鬆症性骨折の負担を軽減することを目的としています。
科学分野:
- 遺伝学と精密医療; 骨の健康と骨粗鬆症研究; 予防医療戦略
背景:
- 遺伝的要因は、骨粗鬆症の発症と骨折リスクに大きく影響します。; 現在の骨粗鬆症スクリーニングガイドラインには、遺伝的リスク評価が組み込まれていません。; 個々の遺伝的素因に基づいた個別化スクリーニングプロトコルの必要性があります。
研究 の 目的:
- PRSを用いた個別化骨粗鬆症スクリーニング年齢を決定すること。; PRSが骨粗鬆症の早期発見を可能にする可能性を評価すること。; 骨粗鬆症の精密予防戦略を進めること。
主な方法:
- UKバイオバンクの223,818人の女性を対象とした前向きコホート研究。; 参加者を低、中、高PRSのサブグループに分類。; 10年間の累積骨粗鬆症リスク、リスク適応スクリーニング年齢、およびリスク進行期間(RAP)を計算しました。
主要な成果:
- 65歳時点で、一般の女性集団の10年間の骨粗鬆症リスクは5.95%です。高PRSの女性はこの閾値に60歳で到達しました。低PRSの女性は69歳でした。高PRSの個人は、中PRSよりも有意に早く(4.99年早く)骨粗鬆症を発症しました。
結論:
- PRSを骨粗鬆症スクリーニングに統合することで、予防に革命をもたらすことができます。; 遺伝的にリスクの高い女性における早期発見は、現在のガイドラインに先行して可能です。; この精密予防アプローチは、骨粗鬆症性骨折の集団負担を大幅に軽減する可能性があります。
関連する概念動画
Genetic Screens
5.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.6K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
384
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
384
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Analysis of Population Pharmacokinetic Data
673
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
673
Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218

